Elan to pay $203 million for off-label marketing

Share this content:
Elan Pharmaceuticals pleaded guilty to a misdemeanor violation for illegally promoting epilepsy drug Zonegran. The firm was also sentenced to pay a criminal fine of $97 million and forfeit $3.6 million in substituted assets, and agreed to pay $102 million to resolve civil allegations. Elan promoted Zonegran for Parkinson's disease, psychiatric disorders and other off-label uses, according to the Department of Justice.

Next Article in Products